Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
50 hedge funds and large institutions have $33.6M invested in Viracta Therapeutics, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 7 closing their positions.
216% more call options, than puts
Call options by funds: $816K | Put options by funds: $258K
0% more funds holding
Funds holding: 50 → 50 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
6.28% less ownership
Funds ownership: 52.26% → 45.98% (-6.3%)
31% less capital invested
Capital invested by funds: $48.8M → $33.6M (-$15.3M)
33% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.3M |
| 2 |
Two Sigma Investments
New York
|
+$218K |
| 3 |
JP Morgan Chase
New York
|
+$189K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$185K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$184K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$6.72M |
| 2 |
Goldman Sachs
New York
|
-$441K |
| 3 |
Millennium Management
New York
|
-$290K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$273K |
| 5 |
TI
Telemetry Investments
New York
|
-$214K |
VIRX Hedge Fund Activity: Q2 2018 in Review
50 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q2 2018, worth a combined $33.6M — down 31% from $48.8M a quarter earlier.
Fund positioning in VIRX was balanced in Q2 2018: 7 funds opened new positions, 7 closed out, 8 added to existing stakes and 12 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.3M. The largest seller was RA Capital Management, exiting entirely with an estimated $6.72M sold.
- 50 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $33.6M of Viracta Therapeutics, Inc. Common Stock stock for Q2 2018, down 31% quarter-over-quarter.
- 7 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q2 2018 and 7 closed out, a net change of 0 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q2 2018 was Sabby Management, an estimated $1.3M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q2 2018 was RA Capital Management, an estimated $6.72M sold.
Based on aggregated 13F filings for Q2 2018.